Stock 301258 SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Suzhou Fushilai Pharmaceutical Co., Ltd.

Equities

301258

CNE1000058W2

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
38.87 CNY -2.83% Intraday chart for Suzhou Fushilai Pharmaceutical Co., Ltd. +38.13% +20.42%
Apr. 22 Suzhou Fushilai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 01 Tranche Update on Suzhou Fushilai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 3,598 2,959
Enterprise Value (EV) 1 2,180 1,542
P/E ratio 19.1 x 26.5 x
Yield 1.48% 1.86%
Capitalization / Revenue 6.33 x 6.05 x
EV / Revenue 3.84 x 3.15 x
EV / EBITDA 10,396,333 x 10,394,403 x
EV / FCF 74,230,430 x 43,429,923 x
FCF Yield 0% 0%
Price to Book 1.91 x 1.52 x
Nbr of stocks (in thousands) 91,670 91,670
Reference price 2 39.25 32.28
Announcement Date 4/17/23 4/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 375.4 452.5 476.8 521.7 568.2 489.3
EBITDA - - - 182.7 209.7 148.4
EBIT 1 101.6 163 162.7 137 158.8 92.89
Operating Margin 27.07% 36.02% 34.12% 26.27% 27.94% 18.98%
Earnings before Tax (EBT) 1 108.2 170.2 164.8 138.4 202.5 128.5
Net income 1 93.27 145.7 141.1 120.2 177.3 112.2
Net margin 24.85% 32.2% 29.58% 23.04% 31.2% 22.93%
EPS 2 1.410 2.160 2.050 1.750 2.060 1.220
Free Cash Flow - 35.28 32.26 86.31 29.37 35.51
FCF margin - 7.8% 6.77% 16.54% 5.17% 7.26%
FCF Conversion (EBITDA) - - - 47.23% 14.01% 23.93%
FCF Conversion (Net income) - 24.21% 22.87% 71.8% 16.57% 31.65%
Dividend per Share 2 0.7500 0.7600 0.7000 0.4000 0.5800 0.6000
Announcement Date 3/22/22 3/22/22 3/22/22 4/26/22 4/17/23 4/22/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 148 216 218 335 1,418 1,417
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - 35.3 32.3 86.3 29.4 35.5
ROE (net income / shareholders' equity) - 28.4% 23.4% 17.6% 13.5% 5.85%
ROA (Net income/ Total Assets) - 15.1% 13.2% 9.74% 6.47% 2.76%
Assets 1 - 965.4 1,068 1,234 2,742 4,072
Book Value Per Share 2 6.740 8.630 9.060 10.80 20.60 21.20
Cash Flow per Share 2 2.240 2.890 1.430 4.830 2.830 3.820
Capex 1 20.1 70.9 65.7 80.7 50.1 41.6
Capex / Sales 5.35% 15.68% 13.78% 15.48% 8.82% 8.51%
Announcement Date 3/22/22 3/22/22 3/22/22 4/26/22 4/17/23 4/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD. Stock Suzhou Fushilai Pharmaceutical Co., Ltd.
+20.42% 507M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 698B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.40% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.46% 328B
ABBVIE INC. Stock AbbVie Inc.
+3.50% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.34% 238B
NOVARTIS AG Stock Novartis AG
+6.68% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 198B
AMGEN INC. Stock Amgen Inc.
+8.62% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301258 Stock
  4. Financials Suzhou Fushilai Pharmaceutical Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW